Stock Scorecard
Stock Summary for CRISPR Therapeutics AG (CRSP) - $53.47 as of 11/19/2025 3:16:04 PM EST
Total Score
6 out of 30
Safety Score
46 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CRSP
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CRSP
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CRSP
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CRSP
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CRSP (46 out of 100)
| Stock Price Rating (Max of 10) | 9 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 7 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 5 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for CRSP
Financial Details for CRSP
Company Overview |
|
|---|---|
| Ticker | CRSP |
| Company Name | CRISPR Therapeutics AG |
| Country | USA |
| Description | Crispr Therapeutics AG (CRSP) is a leading gene editing company at the forefront of innovation, harnessing its proprietary CRISPR/Cas9 technology to develop transformative therapies for severe genetic disorders, including sickle cell disease and beta-thalassemia. Headquartered in Zug, Switzerland, the company is not only advancing its clinical pipeline but also establishing strategic partnerships to accelerate the development and commercialization of its groundbreaking science. With a strong commitment to enhancing patient outcomes and a solid portfolio of potential therapies, Crispr Therapeutics is well-positioned to redefine the future of medicine and play a pivotal role in the biopharmaceutical landscape. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 53.47 |
| Price 4 Years Ago | 75.78 |
| Last Day Price Updated | 11/19/2025 3:16:04 PM EST |
| Last Day Volume | 1,714,748 |
| Average Daily Volume | 2,674,743 |
| 52-Week High | 78.48 |
| 52-Week Low | 30.04 |
| Last Price to 52 Week Low | 78.00% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 42.93 |
| Sector PE | 115.35 |
| 5-Year Average PE | -8.94 |
| Free Cash Flow Ratio | 17.76 |
| Industry Free Cash Flow Ratio | 13.62 |
| Sector Free Cash Flow Ratio | 27.55 |
| Current Ratio Most Recent Quarter | 16.22 |
| Total Cash Per Share | 3.01 |
| Book Value Per Share Most Recent Quarter | 20.41 |
| Price to Book Ratio | 2.75 |
| Industry Price to Book Ratio | 33.51 |
| Sector Price to Book Ratio | 33.20 |
| Price to Sales Ratio Twelve Trailing Months | 132.92 |
| Industry Price to Sales Ratio Twelve Trailing Months | 28.80 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.69 |
| Analyst Buy Ratings | 9 |
| Analyst Strong Buy Ratings | 6 |
Share Statistics |
|
| Total Shares Outstanding | 95,300,000 |
| Market Capitalization | 5,095,691,000 |
| Institutional Ownership | 77.99% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -138.43% |
| Reported EPS 12 Trailing Months | -5.54 |
| Reported EPS Past Year | -4.04 |
| Reported EPS Prior Year | -4.37 |
| Net Income Twelve Trailing Months | -488,297,000 |
| Net Income Past Year | -366,252,000 |
| Net Income Prior Year | -153,610,000 |
| Quarterly Revenue Growth YOY | 47.70% |
| 5-Year Revenue Growth | -34.47% |
| Operating Margin Twelve Trailing Months | -14,855.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 286,497,000 |
| Total Cash Past Year | 298,257,000 |
| Total Cash Prior Year | 389,477,000 |
| Net Cash Position Most Recent Quarter | 286,497,000 |
| Net Cash Position Past Year | 298,257,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 1,932,080,000 |
| Total Stockholder Equity Prior Year | 1,882,803,000 |
| Total Stockholder Equity Most Recent Quarter | 1,915,982,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -303,143,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -3.18 |
| Free Cash Flow Past Year | -144,675,000 |
| Free Cash Flow Prior Year | -269,845,000 |
Options |
|
| Put/Call Ratio | 0.61 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -3.86 |
| MACD Signal | -2.65 |
| 20-Day Bollinger Lower Band | 48.03 |
| 20-Day Bollinger Middle Band | 60.17 |
| 20-Day Bollinger Upper Band | 72.30 |
| Beta | 1.72 |
| RSI | 36.59 |
| 50-Day SMA | 48.93 |
| 150-Day SMA | 53.11 |
| 200-Day SMA | 55.06 |
System |
|
| Modified | 11/19/2025 9:03:40 PM EST |